Systems biology in inflammatory bowel diseases: Ready for prime time

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 339-346

  Polytarchou, Christos ^a   Koukos, Georgios ^a   Iliopoulos, Dimitrios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Data integration; High throughput analysis; Inflammatory bowel disease; Network; Systems biology

Indexed keywords

DNA; PROTEOME; TRANSCRIPTOME;

CHROMATIN; DRUG DEVELOPMENT; ENDOTHELIUM CELL; EPIGENETICS; EPITHELIUM CELL; FIBROBLAST; GENETICS; GENOME; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; METABOLOME; METABOLOMICS; PATHOGENESIS; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; COLITIS, ULCERATIVE; CROHN DISEASE; INFLAMMATORY BOWEL DISEASES; TRENDS; UNITED STATES;

COLITIS, ULCERATIVE; CROHN DISEASE; EPIGENOMICS; HUMANS; INFLAMMATORY BOWEL DISEASES; METABOLOMICS; PROTEOMICS; SYSTEMS BIOLOGY; UNITED STATES;

EID: 84902280684     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000081     Document Type: Review

References (91)

1. Fiocchi C. IBD: Advances in pathogenesis, complications, diagnosis and therapy. Curr Opin Gastroenterol 2012; 28:297-300.
2. Yu CG, Huang Q. Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. J Dig Dis 2013; 14:513-517.
3. Vetrano S, Danese S. Colitis, microbiota, and colon cancer: An infernal triangle. Gastroenterology 2013; 144:461-463.
4. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13:R79.
5. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119-124.
6. Blumberg R. What are innate and acquired immunity, and why are they important in IBD? Inflamm Bowel Dis 2008; 14 (Suppl 2):S93-S94.
7. Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20:6-21.
8. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013; 62:1653-1664.
9. D'Alessio S, Tacconi C, Fiocchi C, et al. Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29:608-613.
10. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-tomesenchymal transition: A novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179:2660-2673.
11. Raleigh DR, Boe DM, Yu D, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol 2011; 193:565-582.
12. Al-Sadi R, Guo S, Dokladny K, et al. Mechanism of interleukin-1beta inducedincrease in mouse intestinal permeability in vivo. J Interferon Cytokine Res 2012; 32:474-484.
13. Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 2011; 141:1323-1333.
14. Kim M, Lee KH, Yoon SW, et al. Analytical tools and databases for metagenomics in the next-generation sequencing era. Genomics Inform 2013; 11:102-113.
15. Di Bella JM, Bao Y, GloorGB, et al. High throughput sequencing methods and analysis for microbiome research. J Microbiol Methods 2013; 95:401-414.
16. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature 1998; 393:440-442.
17. Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet 2013; 9:e1003723.
18. Fiocchi C. Towards a 'cure' for IBD. Dig Dis 2012; 30:428-433.
19. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: The emerging role of epigenetics. Gastroenterology 2013; 145:293-308.
20. Consortium EP, Bernstein BE, Birney E, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74.
21. McGovern DP,Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42:332-337.
22. Wei Z, Wang W, Bradfield J, et al. Large sample size, wide variant spectrum, and advanced machine-learning technique boost risk prediction for inflammatory bowel disease. Am J Hum Genet 2013; 92:1008-1012.
23. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin Gastroenterol Hepatol 2013; 11:22-26.
24. Ellinghaus D, Zhang H, Zeissig S, et al. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology 2013; 145:339-347.
25. Christodoulou K, Wiskin AE, Gibson J, et al. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. Gut 2013; 62:977-984.
26. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011; 68:1681-1702.
27. Nimmo ER, Prendergast JG, Aldhous MC, et al. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis 2012; 18:889-899.
28. Harris RA, Nagy-Szakal D, Pedersen N, et al. Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18:2334-2341.
29. Hasler R, Feng Z, Backdahl L, et al. A functional methylome map of ulcerative colitis. Genome Res 2012; 22:2130-2137.
30. Gu H, Smith ZD, Bock C, et al. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc 2011; 6:468-481.
31. Sadler T, Scarpa M, Rieder F, et al. Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition. Inflamm Bowel Dis 2013; 19:1354-1364.
32. Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013; 62:967-976.
33. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26:317-325.
34. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008; 135:1624-1635; e24.
35. Koukos G, Polytarchou C, Kaplan JL, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 2013; 145:842-852; e2.
36. Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 2010; 25 (Suppl 1):S129-S133.
37. Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2010; 16:1729-1738.
38. Ong FS, Lin JC, Das K, et al. Translational utility of next-generation sequencing. Genomics 2013; 102:137-139.
39. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422:193-197.
40. Bonetta L. Protein-protein interactions: interactome under construction. Nature 2010; 468:851-854.
41. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis 2009; 15:616-629.
42. Barcelo-Batllori S, Andre M, Servis C, et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2002; 2:551-560.
43. Hardwidge PR, Rodriguez-Escudero I, Goode D, et al. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J Biol Chem 2004; 279:20127-20136.
44. Weichart D, Gobom J, Klopfleisch S, et al. Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells. J Biol Chem 2006; 281:2380-2389.
45. Shkoda A, Werner T, Daniel H, et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res 2007; 6:1114-1125.
46. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis 2011; 17:875-883.
47. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006; 6:5322-5331.
48. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007; 73:1422-1433.
49. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study. Clin Biochem 2008; 41:960-967.
50. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007; 21:4142-4148.
51. Cooney JM, Barnett MP, Brewster D, et al. Proteomic analysis of colon tissue from interleukin-10 gene-deficient mice fed polyunsaturated fatty acids with comparison to transcriptomic analysis. J Proteome Res 2012; 11:1065-1077.
52. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: The apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13:263-269.
53. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012; 159:313-325.
54. De Preter V, Verbeke K. Metabolomics as a diagnostic tool in gastroenterology. World J Gastrointest Pharmacol Ther 2013; 4:97-107.
55. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6:546-551.
56. Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10:4208-4218.
57. Zhang Y, Lin L, Xu Y, et al. 1H NMR-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochem Biophys Res Commun 2013; 433:547-551.
58. Stephens NS, Siffledeen J, Su X, et al. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 2013; 7:e42-e48.
59. Schicho R, Shaykhutdinov R, Ngo J, et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012; 11:3344-3357.
60. Hisamatsu T, Okamoto S, Hashimoto M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One 2012; 7:e31131.
61. Ooi M, Nishiumi S, Yoshie T, et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011; 60:831-840.
62. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J 2008; 2:716-727.
63. Baur P, Martin FP, Gruber L, et al. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF(DeltaARE/WT) mouse model. J Proteome Res 2011; 10:5523-5535.
64. Tavazoie S, Hughes JD, Campbell MJ, et al. Systematic determination of genetic network architecture. Nat Genet 1999; 22:281-285.
65. Milo R, Shen-Orr S, Itzkovitz S, et al. Network motifs: simple building blocks of complex networks. Science 2002; 298:824-827.
66. Alon U. Network motifs: Theory and experimental approaches. Nat Rev Genet 2007; 8:450-461.
67. Gossage L, Eisen T. Targeting multiple kinase pathways: A change in paradigm. Clin Cancer Res 2010; 16:1973-1978.
68. Berg J, Lassig M. Correlated random networks. Phys Rev Lett 2002; 89:228701.
69. Bock M, Scharp T, Talnikar C, et al. BooleSim: An interactive Boolean network simulator. Bioinformatics 2014; 30:131-132.
70. Gao YM, Xu P, Wang XH, et al. The complex fluctuations of probabilistic Boolean networks. Biosystems 2013; 114:78-84.
71. Liepe J, Kirk P, Filippi S, et al. A framework for parameter estimation and model selection from experimental data in systems biology using approximate Bayesian computation. Nat Protoc 2014; 9:439-456.
72. Marino S, Baxter NT, Huffnagle GB, et al. Mathematical modeling of primary succession of murine intestinal microbiota. Proc Natl Acad Sci U S A 2014; 111:439-444.
73. Xun X, Cao J, Mallick B, et al. Parameter estimation of partial differential equation models. J Am Stat Assoc 2013; 108:1009-1020.
74. Karl S, Dandekar T. Jimena: efficient computing and system state identification for genetic regulatory networks. BMC Bioinformatics 2013; 14:306.
75. Bock M, Ogishima S, Tanaka H, et al. Hub-centered gene network reconstruction using automatic relevance determination. PLoS One 2012; 7:e35077.
76. Neal ML, Gennari JH, Arts T, et al. Advances in semantic representation for multiscale biosimulation: A case study in merging models. Pac Symp Biocomput 2009; 14:304-315.
77. Mi H, Muruganujan A, Demir E, et al. BioPAX support in CellDesigner. Bioinformatics 2011; 27:3437-3438.
78. Tomita M, Hashimoto K, Takahashi K, et al. E-CELL: software environment for whole-cell simulation. Bioinformatics 1999; 15:72-84.
79. Ganter B, Giroux CN. Emerging applications of network and pathway analysis in drug discovery and development. Curr Opin Drug Discov Devel 2008; 11:86-94.
80. Mahowald MA, Rey FE, Seedorf H, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A 2009; 106:5859-5864.
81. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60:631-637.
82. McNiven EM, German JB, Slupsky CM. Analytical metabolomics: nutritional opportunities for personalized health. J Nutr Biochem 2011; 22:995-1002.
83. Olivares M, Laparra JM, Sanz Y. Host genotype, intestinal microbiota and inflammatory disorders. Br J Nutr 2013; 109 (Suppl 2):S76-S80.
84. Presley LL, Ye J, Li X, et al. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosalluminal interface. Inflamm Bowel Dis 2012; 18:409-417.
85. McHardy IH, Goudarzi M, Tong M, et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome 2013; 1:17.
86. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136:585-595; e5.
87. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflamm Bowel Dis 2013; 19:1983-1989.
88. Al-Sadi R, Guo S, Ye D, et al. TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1. Am J Pathol 2013; 183:1871-1884.
89. Tang Y, Clayburgh DR, Mittal N, et al. Epithelial NF-kappaB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation. Am J Pathol 2010; 176:158-167.
90. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9:799-809.
91. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using geneexpression signatures to connect small molecules, genes and disease. Science 2006; 29:1929-1935.